Quotables
"This is the patent age of new inventions for killing bodies, and for saving souls. All propagated with the best intentions."
Lord Byron ;
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8182815 | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using ... | 05/22/2012 |
| 8182814 | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11. ... | 05/22/2012 |
| 8178097 | Methods of treatment utilizing binding proteins of the interleukin-21 receptor The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of ... | 05/15/2012 |
| 8163287 | Combination therapy of her expressing tumors The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors. ... | 04/24/2012 |
| 8124088 | Methods of treatment using anti-IL-22RA antibodies The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL... | 02/28/2012 |
| 8119136 | Methods of modulating apoptosis by administration of relaxin agonists or antagonists The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides... | 02/21/2012 |
| 8101182 | Methods and compositions for treating allergic diseases Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling. ... | 01/24/2012 |
| 8097255 | Mammalian receptor protein DCRS5; methods of treatment Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described... | 01/17/2012 |
| 8092804 | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. ... | 01/10/2012 |
| 8080248 | Method of treating rheumatoid arthritis with an IL-6R antibody The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include adm... | 12/20/2011 |
| 8075892 | Treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an an... | 12/13/2011 |
| 8067000 | Cancer treatment with endothelin receptor antagonists The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or... | 11/29/2011 |
| 8067001 | Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been e... | 11/29/2011 |
| 8043617 | Human antibodies to human IL-6 receptor A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-b... | 10/25/2011 |
| 8043618 | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using ... | 10/25/2011 |
| 8038996 | Composition and method for cancer treatment Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided. ... | 10/18/2011 |
| 8029794 | Combining therapies targeting multiple toll-like receptors The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions ... | 10/04/2011 |
| 8029793 | Methods for inhibiting cell proliferation Provided are proliferation inhibitors for cells whose proliferation is stimulated by PTHrP (34-53), comprising a substance inhibiting the binding of PTHrP (1-34) to its receptor. ... | 10/04/2011 |
| 8012481 | Composition and method for inducing or restoring locomotor functions in an animal The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movem... | 09/06/2011 |
| 8003103 | High affinity human antibodies to human IL-18 receptor An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18Rα), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 7... | 08/23/2011 |
| 7998482 | Methods and reagents for the analysis and purification of polysaccharides The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to puri... | 08/16/2011 |
| 7993643 | Uses of human monoclonal antibodies against oxidized LDL receptor Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by g... | 08/09/2011 |
| 7993644 | Tissue factor antibodies and uses thereof The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the... | 08/09/2011 |
| 7988966 | Method for the potentiation of opioid analgesics effects on pain According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain. ... | 08/02/2011 |
| 7981421 | Combinations of antibodies selective for DR5 and other therapeutic agents An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination w... | 07/19/2011 |
| 7968093 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivative... | 06/28/2011 |
| 7951775 | Methods and pharmaceutical compositions for GnRH-I and GnRH-II modulation of T-cell activity, adhesion, migration and extravasation Methods and compositions comprising GnRH-I and GnRH-II, GnRH-I and GnRH-II antibodies, anti-receptor antibodies, polynucleotide constructs and GnRH-I and GnRH-II analogs for immune enhancement and suppression, prevention and treatment of diseases and conditions char... | 05/31/2011 |
| 7943134 | Compositions and methods for identifying response targets and treating flavivirus infection responses Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flaviv... | 05/17/2011 |
| 7919093 | Roles for dual endothelin-1/angiotensin II receptor (Dear) in hypertension and angiogenesis The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-1/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention di... | 04/05/2011 |
| 7906120 | Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-6... | 03/15/2011 |
| 7892549 | Treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an an... | 02/22/2011 |
| 7892550 | Anti-cmet antibodies The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. ... | 02/22/2011 |
| 7887806 | Mammalian receptor proteins DCRS5; method of treatment Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described... | 02/15/2011 |
| 7887805 | Recombinant anti-epidermal growth factor receptor antibody compositions The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synerg... | 02/15/2011 |
| 7879327 | Medicament for treating cancer A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient. ... | 02/01/2011 |
| 7871620 | Immunoliposomes that optimize internationalization into target cells The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker... | 01/18/2011 |
| 7871619 | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described. ... | 01/18/2011 |
| 7862817 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... | 01/04/2011 |
| 7850969 | Leukocyte inactivation module The present invention provides a module for reducing the activity of leukocytes which comprises a carrier and a ligand that is linked to the carrier and is suitable for interacting with a leukocyte receptor. Furthermore, the present invention provides a process for ... | 12/14/2010 |
| 7846441 | Treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an an... | 12/07/2010 |
